Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
G protein-coupled receptor 37 is a negative regulator of oligodendrocyte differentiation and myelination.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.
Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Multiple Sclerosis.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
Mitoxantrone-related acute leukemia in MS: An open or closed book?

Pages